← Research ProtocolsMazdutide
STUDIED EXPOSURE MAP / 2026
Mazdutide
tested in research.
The actual doses, concentrations or exposure levels reported by the source — kept attached to route, population, timeframe and evidence type.
HUMAN / RANDOMIZED PHASE 2LANCET DIABETES & ENDOCRINOLOGYSTUDIED EXPOSURE ≠ RECOMMENDED DOSE
STUDIED EXPOSURE / SOURCE DATANumbers below describe this research source only.
3→6 mg
SC weekly; 3 mg maintained to week 32 then 6 mg
10 mg
SC · once weekly target
16 mg
SC · once weekly target
Context: This recent phase-2 trial tested a broad target-dose range. The 3→6 mg arm had a defined protocol transition; the display preserves that distinction.
NOT A DOSING GUIDEENHANCED is reporting what researchers administered or tested. It does not convert these numbers into a personal dose, reconstitution plan, cycle, titration schedule or recommendation.
SOURCE / LANCET DIABETES & ENDOCRINOLOGY
Efficacy and safety of mazdutide in adults with obesity or overweight: US phase 2 trial
Study design and tested exposure are separated from recommendation. Route and population stay visible so the numbers cannot be read without context.
2026
01 / DESIGNMulticenter · randomized · double-blind · placebo-controlled phase 2
02 / POPULATION / MODELAdults with obesity or overweight without type 2 diabetes
03 / ROUTESubcutaneous · once weekly
04 / TIMEFRAME48 weeks
05 / PRIMARY QUESTIONEfficacy, safety and tolerability across a high-dose range
It supports a factual statement about the exposure tested in this research source. It does not establish that the same exposure is appropriate, effective or safe outside that source.
Broader research index. This entity is not presented here as an ENHANCED catalogue compound.
Study exposure ≠ personal protocol. Animal doses are never converted to human-equivalent amounts here. IV, topical, oral, intranasal and subcutaneous exposures are not treated as interchangeable.